Christopher R Pallas
A5068531889- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Biosimilars and Bioanalytical Methods
- Hemoglobinopathies and Related Disorders
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
Levine Cancer Institute
2021-2024
e18545 Background: Health disparity in squamous cell carcinoma of the head and neck (SCCHN) is well-recognized. Privately insured SCCHN patients are observed to have better outcomes, but underlying factors poorly understood. Oncology nurse navigators (ONN) a well-established role focused on optimizing cancer care patient experience. The effects ONN bridging health disparities not been demonstrated. We sought characterize outcome diagnosed with oropharyngeal cancers assess if implementation...
e20539 Background: The PACIFIC trial ushered in a paradigm shift the management of unresectable, non-metastatic non-small cell lung cancer (NSCLC), demonstrating improvement 12,24,36-month overall survival (OS) and leading to 2018 FDA approval for durvalumab unresectable or locally advanced stage III NSCLC. With almost 3 years approval, we performed retrospective analysis patient experiences outcomes at Levine Cancer Institute analyzing data assess potential points clinical significance....